---
title: "XUERONG released its performance for the first three quarters, with a net loss of 62.3484 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261248927.md"
description: "According to the Zhitong Finance APP, XUERONG released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.325 billion yuan, a year-on-year decrease of 19.26%. The net loss attributable to shareholders of the listed company was 62.3484 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 85.1896 million yuan. The basic loss per share was 0.11 yuan"
datetime: "2025-10-15T11:49:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261248927.md)
  - [en](https://longbridge.com/en/news/261248927.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261248927.md)
---

# XUERONG released its performance for the first three quarters, with a net loss of 62.3484 million yuan

According to the Zhitong Finance APP, XUERONG (300511.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.325 billion yuan, a year-on-year decrease of 19.26%. The net loss attributable to shareholders of the listed company was 62.3484 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 85.1896 million yuan. The basic loss per share was 0.11 yuan

### Related Stocks

- [300511.CN](https://longbridge.com/en/quote/300511.CN.md)

## Related News & Research

- [Microbiotica reports positive results for MB097 in advanced melanoma](https://longbridge.com/en/news/286740265.md)
- [Seegene Launches Allplex™ MDRO Assay Under IVDR: Expanding AMR Testing Portfolio in Europe](https://longbridge.com/en/news/287237973.md)
- [08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine](https://longbridge.com/en/news/286917434.md)
- [Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer](https://longbridge.com/en/news/286856224.md)
- [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)